TY  - JOUR
AU  - Bonomi, P D
AU  - Gandara, D
AU  - Hirsch, F R
AU  - Kerr, K M
AU  - Obasaju, C
AU  - Paz Ares, Luis Gonzaga
AU  - Bellomo, C
AU  - Bradley, J D
AU  - Bunn, P A
AU  - Culligan, M
AU  - Jett, J R
AU  - Kim, E S
AU  - Langer, C J
AU  - Natale, R B
AU  - Novello, S
AU  - Pérol, M
AU  - Ramalingam, S S
AU  - Reck, M
AU  - Reynolds, C H
AU  - Smit, E F
AU  - Socinski, M A
AU  - Spigel, D R
AU  - Vansteenkiste, J F
AU  - Wakelee, H
AU  - Thatcher, N
PY  - 2018
DO  - 10.1093/annonc/mdy196
SN  - 0923-7534
UR  - http://hdl.handle.net/20.500.12105/6820
AB  - Background: Upregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR monoclonal antibodies...
LA  - eng
KW  - GROWTH-FACTOR RECEPTOR
KW  - PHASE-III TRIAL
KW  - CLINICAL-PRACTICE GUIDELINES
KW  - CISPLATIN PLUS GEMCITABINE
KW  - OPEN-LABEL
KW  - STAGE IV
KW  - 1ST-LINE THERAPY
KW  - FOLLOW-UP
KW  - CETUXIMAB
KW  - CHEMOTHERAPY
TI  - Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
TY  - journal article
ER  -